Aardvark Therapeutics, Inc.
AARD · XNASCIK 1774857fmd_1GGBMJZ5SETG9Y6VFPT4X43MJFManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2024 to Sep 30, 2026, 11 periods
| Line item | FY2024 | FY2025 |
|---|---|---|
| Total interest income | 2 | 5 |
| Total revenues | – | 0 |
| Research and development | 17 | 49 |
| Compensation and benefits | 4 | 12 |
| Total operating expenses | 23 | 63 |
| Operating income | (23) | (63) |
| Interest and investment income | 2 | 5 |
| Other non-operating income (expense) | 2 | 5 |
| Income tax expense | 0 | 0 |
| Net income | (21) | (58) |